ZGNX - Zogenix prices $200M convertible senior notes offering

Zogenix (ZGNX) prices $200M 2.75% convertible senior notes due 2027 in a private offering to institutional buyers.Initial purchasers has an option an additional  $30M From and after July 1, 2027, noteholders may convert their notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date.Net proceeds of ~$193.6M will be used to fund development and commercialization of Fintepla in Dravet syndrome, Lennox-Gastaut syndrome, and other potential indications, to fund the development of MT1621 in TK2 deficiency and other general corporate purposes, such as working capital and general and administrative expenses. Source: Press Release

For further details see:

Zogenix prices $200M convertible senior notes offering